Osaka, Japan

Shigeki Sakamaki

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shigeki Sakamaki: Innovator in Pharmaceutical Compounds

Introduction

Shigeki Sakamaki is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications. With a total of 2 patents, Sakamaki's work focuses on innovative solutions for various medical conditions.

Latest Patents

Sakamaki's latest patents include groundbreaking compounds that are modulators of RXFP1. These compounds are designed to treat or prevent diseases such as heart failure, chronic kidney disease, and acute kidney injury. The specifications detail the use of these compounds and their pharmaceutically acceptable salts, highlighting their potential as therapeutic agents. Additionally, he has developed novel indole derivatives that act as SGLT inhibitors, which are useful in the treatment and prevention of diabetes and related conditions.

Career Highlights

Throughout his career, Sakamaki has worked with prominent companies in the pharmaceutical industry, including Mitsubishi Tanabe Pharma Corporation and AstraZeneca. His experience in these organizations has allowed him to contribute to significant advancements in drug development and therapeutic solutions.

Collaborations

Sakamaki has collaborated with esteemed colleagues such as Sumihiro Nomura and Kenneth Lars Granberg. These partnerships have further enhanced his research and innovation in the pharmaceutical field.

Conclusion

Shigeki Sakamaki is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact the treatment of various medical conditions. His innovative contributions continue to advance the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…